N-1-methylnicotinamide
Alternative Names: 1-methylnicotinamide cation; 1-MNA; MNA; NMN; TRIA 662; TRIA-662; TrigonellinamideLatest Information Update: 02 Oct 2021
At a glance
- Originator Technical University of Lodz
- Developer Cortria Corporation
- Class Amides; Antihyperlipidaemics; Nicotinic acids; Pyridinium compounds; Small molecules; Vitamins
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hyperlipidaemia
Most Recent Events
- 01 Oct 2015 Cortria Corporation completes a phase II trial for Hyperlipidaemia in Canada (NCT02008084)
- 19 Jun 2015 Phase-II/III development for Hyperlipidaemia is ongoing in Canada
- 06 Dec 2013 Cortria Corporation initiates enrolment in a phase II trial for Hyperlipidaemia in Canada (NCT02008084)